A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
Article
[키워드] Administered
Adverse
antibody
approved
arthralgia
Arthritis
cause
characterized
Chikungunya virus
clinical trial
Concentration
conducted
detectable
disease
dose
dose-dependent
Effect
evaluate
evaluated
Ex vivo
expression
Fever
functional
healthy
Human
IgG
IgG level
immunocompromised individual
Immunoglobulin
in vivo
Infant
Infection
Infectious diseases
interim analysis
intravenous
knowledge
Messenger RNA
Mild
moderate
monoclonal
monoclonal antibody
mRNA
mRNA-based
Neutralizing
Neutralizing activity
neutralizing antibody
offer
participant
patients
phase 1 trial
Placebo
placebo-controlled
plasma concentration
predicted
Preventive medicine
Primary outcome
Randomized
Rash
serum
severity
single dose
therapeutic
therapeutic use
therapy
Tolerability
Treatment
Trial
viral infection
[DOI] 10.1038/s41591-021-01573-6 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41591-021-01573-6 PMC 바로가기 [Article Type] Article